These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31046913)

  • 1. Morphea secondary to interferon beta1b injection: a case and review of the literature.
    Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment.
    Mozafari N; Saffaei A; Alizadeh M; Shabani M
    J Cosmet Dermatol; 2020 Apr; 19(4):951-953. PubMed ID: 31436377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review.
    Sirbu CA; Dantes E; Plesa CF; Docu Axelerad A; Ghinescu MC
    Medicina (Kaunas); 2020 Apr; 56(4):. PubMed ID: 32344653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
    Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
    Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
    Kim YJ; Lee HY; Lee JY; Yoon TY
    Int J Dermatol; 2015 Apr; 54(4):456-8. PubMed ID: 23786157
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Logan-Clubb L; Stacy M
    J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta1b for the treatment of multiple sclerosis.
    Lam S; Wang S; Gottesman M
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta injection site reactions in patients with multiple sclerosis.
    Maurelli M; Bergamaschi R; Antonini A; Fargnoli MC; Puma E; Mallucci G; Totaro R; Girolomoni G
    J Dermatolog Treat; 2018 Dec; 29(8):831-834. PubMed ID: 29671656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sweet syndrome associated with interferon.
    Rodriguez-Lojo R; Castiñeiras I; Juarez Y; Lueiro M; Armesto A; Fernandez-Diaz ML
    Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
    Gottesman MH; Friedman-Urevich S
    Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
    Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis.
    Rosa DJ; Matias Fde A; Cedrim SD; Machado RF; Sá AA; Silva VC
    An Bras Dermatol; 2011; 86(2):336-8. PubMed ID: 21603818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.
    O'Sullivan SS; Cronin EM; Sweeney BJ; Bourke JF; Fitzgibbon J
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1382-3. PubMed ID: 16782776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.